Press release
GM2 Gangliosidosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Sanofi, IntraBio, Taysha Gene Therapies, JCR Pharma, Azafaros B.V., Allievex Corp., Recursion, Polaryx
"GM2 Gangliosidosis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the GM2 Gangliosidosis Therapeutics Market.
The report provides a detailed description of the GM2 Gangliosidosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the GM2 Gangliosidosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
GM2 Gangliosidosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing GM2 Gangliosidosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for GM2 Gangliosidosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging GM2 Gangliosidosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the GM2 Gangliosidosis treatment market.
Learn More about the Clinical and Commercial Development Activities in the GM2 Gangliosidosis Therapeutics Domain @
https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
GM2 Gangliosidosis Therapeutics Analysis
The GM2 (monosialoganglioside2) gangliosidoses are caused by mutations in the α- and β-subunits of βhexosaminidase, named Tay-Sachs disease (TSD) and Sandhoff-Jatzkewitz disease (or Sandhoff disease, SD) respectively, and mutations in the GM2 activator protein, GM2 activator protein deficiency. These are emblematic neuronopathic Lysosomal Storage Diseases (LSDs), that are relentlessly fatal and clinically indistinguishable but for subtle visceral and skeletal features in SD.
Several approaches have been tested for the development of specific treatments for GM2 gangliosidoses. These strategies range from traditional enzyme replacement therapy alternatives to novel biotechnological tools such as CRISPR/Cas9 and prime editing, with promising results both in vitro and in vivo. Although some of these developments have been translated to clinical trials, there is not an approved treatment for TSD, or SD variant yet.
There are approx. 8+ key companies developing therapies for GM2 Gangliosidosis. Currently, Sanofi is leaving the therapeutics market with its GM2 Gangliosidosis drug candidates in the most advanced stage of clinical development.
GM2 Gangliosidosis Companies in the Therapeutics Market Include:
• Sanofi
• Sio Gene Therapies
• IntraBio Inc.
• Taysha Gene Therapies
• JCR Pharmaceuticals
• Azafaros B.V.
• Allievex Corp.
• Recursion
• Polaryx
And Many Others
Emerging and Marketed GM2 Gangliosidosis Therapies Covered in the Report Include:
• Venglustat: Sanofi
• AXO-AAV-GM2: Sio Gene Therapies
And Many More
Get an in-depth Assessment of the Emerging Therapies and GM2 Gangliosidosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging GM2 Gangliosidosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
GM2 Gangliosidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Request for Sample PDF to Understand More About the GM2 Gangliosidosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. GM2 Gangliosidosis Current Treatment Patterns
4. GM2 Gangliosidosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. GM2 Gangliosidosis Late-Stage Products (Phase-III)
7. GM2 Gangliosidosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. GM2 Gangliosidosis Discontinued Products
13. GM2 Gangliosidosis Product Profiles
14. GM2 Gangliosidosis Companies
15. GM2 Gangliosidosis Drugs
16. Dormant and Discontinued Products
17. GM2 Gangliosidosis Unmet Needs
18. GM2 Gangliosidosis Future Perspectives
19. GM2 Gangliosidosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices
Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology
Other Trending Healthcare Reports by DelveInsight
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market
Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight
https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market
Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Eczema Market
https://www.delveinsight.com/report-store/eczema-market
Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Hemostats Market
https://www.delveinsight.com/report-store/hemostats-market
Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
Peripheral Vascular Devices Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market
Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market
Hemostasis Market
https://www.delveinsight.com/report-store/hemostasis-market
Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market
Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market
Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market
Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights
Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market
Panuveitis Market
https://www.delveinsight.com/report-store/panuveitis-market
Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market
mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market
Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market
Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market
Audiology Devices Market
https://www.delveinsight.com/report-store/audiology-devices-market
Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market
Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
Cancer Vaccines Market
https://www.delveinsight.com/report-store/cancer-vaccines-market
CAR-T Pipeline Insight
https://www.delveinsight.com/report-store/car-t-pipeline-insight
Concussions Market
https://www.delveinsight.com/report-store/concussions-market
Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Physiotherapy Equipment Market
https://www.delveinsight.com/report-store/physiotherapy-equipment-market
Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market
Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market
Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market
Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market
Migraine Market
https://www.delveinsight.com/report-store/migraine-market
Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight
Renal Vasculitis Market
https://www.delveinsight.com/report-store/renal-vasculitis-market
Dense Deposit Disease Market
https://www.delveinsight.com/report-store/dense-deposit-disease-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM2 Gangliosidosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Sanofi, IntraBio, Taysha Gene Therapies, JCR Pharma, Azafaros B.V., Allievex Corp., Recursion, Polaryx here
News-ID: 3296400 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for GM2
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 gangliosidosis is a group of rare, inherited lysosomal storage disorders caused by mutations in the HEXA, HEXB, or GM2A genes, leading to defective β-hexosaminidase enzyme activity. This results in the accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration. The most common forms include Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need…
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approv …
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the F …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging …
GM2 Gangliosidosis pipeline constitutes 8+ key companies continuously working towards developing 8+ GM2 Gangliosidosis treatment therapies, analyzes DelveInsight
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic…
